ACAD
31.43
-2.07
-6.18%
AEMD
6.01
-0.13
-2.12%
APRI
0.4
-0.07
-14.89%
ARNA
1.81
-0.1
-5.24%
ATEC
0.28
0.00
-0.99%
CNAT
2.04
-0.09
-4.23%
CRXM
0.17
+0.02
+11.96%
CYTX
2.02
+0.02
+1.00%
DXCM
77.46
-0.13
-0.17%
GNMK
8.35
-0.62
-6.91%
HALO
8.44
-0.75
-8.16%
ILMN
138.91
-7.68
-5.24%
INNV
0.23
+0.01
+2.61%
INO
9.17
-0.68
-6.90%
ISCO
2.05
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
111.79
-3.32
-2.88%
LPTN
2.18
-0.18
-7.63%
MBVX
0.553
-0.028
-4.7414%
MEIP
1.36
+0.02
+1.49%
MNOV
7
-0.11
-1.55%
MRTX
5.98
-0.48
-7.43%
MSTX
0.45
-0.007
-1.4683%
NBIX
43.28
-1.31
-2.94%
NUVA
57.93
-0.93
-1.58%
ONCS
1.63
+0.03
+1.87%
ONVO
3.35
-0.1
-2.90%
OREX
0.449
-0.049
-9.8614%
OTIC
15.58
-0.67
-4.12%
QDEL
17.09
-0.77
-4.31%
RCPT
231.96
0.00
0.00%
RGLS
5.29
-0.45
-7.84%
RMD
60.52
-3.56
-5.56%
SCIE
0.005
0.00
-5.5556%
SPHS
1.86
-0.03
-1.59%
SRNE
5.62
-0.26
-4.42%
TROV
4.55
-0.25
-5.21%
VICL
4.47
-0.13
-2.83%
VOLC
18
0.00
0.00%
ZGNX
8.09
-0.32
-3.80%
ACAD
31.43
-2.07
-6.18%
AEMD
6.01
-0.13
-2.12%
APRI
0.4
-0.07
-14.89%
ARNA
1.81
-0.1
-5.24%
ATEC
0.28
0.00
-0.99%
CNAT
2.04
-0.09
-4.23%
CRXM
0.17
+0.02
+11.96%
CYTX
2.02
+0.02
+1.00%
DXCM
77.46
-0.13
-0.17%
GNMK
8.35
-0.62
-6.91%
HALO
8.44
-0.75
-8.16%
ILMN
138.91
-7.68
-5.24%
INNV
0.23
+0.01
+2.61%
INO
9.17
-0.68
-6.90%
ISCO
2.05
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
111.79
-3.32
-2.88%
LPTN
2.18
-0.18
-7.63%
MBVX
0.553
-0.028
-4.7414%
MEIP
1.36
+0.02
+1.49%
MNOV
7
-0.11
-1.55%
MRTX
5.98
-0.48
-7.43%
MSTX
0.45
-0.007
-1.4683%
NBIX
43.28
-1.31
-2.94%
NUVA
57.93
-0.93
-1.58%
ONCS
1.63
+0.03
+1.87%
ONVO
3.35
-0.1
-2.90%
OREX
0.449
-0.049
-9.8614%
OTIC
15.58
-0.67
-4.12%
QDEL
17.09
-0.77
-4.31%
RCPT
231.96
0.00
0.00%
RGLS
5.29
-0.45
-7.84%
RMD
60.52
-3.56
-5.56%
SCIE
0.005
0.00
-5.5556%
SPHS
1.86
-0.03
-1.59%
SRNE
5.62
-0.26
-4.42%
TROV
4.55
-0.25
-5.21%
VICL
4.47
-0.13
-2.83%
VOLC
18
0.00
0.00%
ZGNX
8.09
-0.32
-3.80%
Home » Archive by Category

Xconomy

Synthetic Biology Primer: In Conversation With Richard Kitney, Part 1

December 31, 2015 – 3:00 am

“Synthetic biology” has always been a puzzling term to me. Prosthetic limbs are synthetic. Knee replacements are synthetic. Splicing the gene from one organism into another, a practice…

[[Click headline to continue reading.]]

Synthetic Biology Primer: In Conversation With Richard Kitney, Part 1

December 31, 2015 – 3:00 am

“Synthetic biology” has always been a puzzling term to me. Prosthetic limbs are synthetic. Knee replacements are synthetic. Splicing the gene from one organism into another, a practice…

[[Click headline to continue reading.]]

Synthetic Biology Primer: In Conversation With Richard Kitney, Part 1

December 31, 2015 – 3:00 am

“Synthetic biology” has always been a puzzling term to me. Prosthetic limbs are synthetic. Knee replacements are synthetic. Splicing the gene from one organism into another, a practice…

[[Click headline to continue reading.]]

Synthetic Biology Primer: In Conversation With Richard Kitney, Part 1

December 31, 2015 – 3:00 am

“Synthetic biology” has always been a puzzling term to me. Prosthetic limbs are synthetic. Knee replacements are synthetic. Splicing the gene from one organism into another, a practice…

[[Click headline to continue reading.]]

Synthetic Biology Primer: In Conversation With Richard Kitney, Part 1

December 31, 2015 – 3:00 am

“Synthetic biology” has always been a puzzling term to me. Prosthetic limbs are synthetic. Knee replacements are synthetic. Splicing the gene from one organism into another, a practice…

[[Click headline to continue reading.]]

Thong Le: Biotech Thoughts On Pitches, Prices, Diversity, And Stress

December 30, 2015 – 4:00 am

Thong Le is the CEO of Accelerator, a Seattle biotech venture fund and incubator more than a decade old. Le took over in early 2014 and is overseeing a cross-country expansion. A second Accelerator…

[[Click headline to continue reading.]]

Thong Le: Biotech Thoughts On Pitches, Prices, Diversity, And Stress

December 30, 2015 – 4:00 am

Thong Le is the CEO of Accelerator, a Seattle biotech venture fund and incubator more than a decade old. Le took over in early 2014 and is overseeing a cross-country expansion. A second Accelerator…

[[Click headline to continue reading.]]

Innovation vs. Healthcare Spending: Biotech’s Biggest Looming Challenge

December 28, 2015 – 1:01 am

Let’s start with the good news. We are at the beginning of a transformation in human health, treating diseases in ways that we could only speculate about in the recent past. While biology isn’t quite…

[[Click headline to continue reading.]]

Innovation vs. Healthcare Spending: Biotech’s Biggest Looming Challenge

December 28, 2015 – 1:01 am

Let’s start with the good news. We are at the beginning of a transformation in human health, treating diseases in ways that we could only speculate about in the recent past. While biology isn’t quite…

[[Click headline to continue reading.]]

Innovation vs. Healthcare Spending: Biotech’s Biggest Looming Challenge

December 28, 2015 – 1:01 am

Let’s start with the good news. We are at the beginning of a transformation in human health, treating diseases in ways that we could only speculate about in the recent past. While biology isn’t quite…

[[Click headline to continue reading.]]